Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-229-5872
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.70 million
Profitability
Miscellaneous
Employees124
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme Inc (NASDAQ:EPZM) announced its quarterly earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.02. The biopharmaceutical company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $0.32 million. The company's quarterly revenue was down 50.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.42) EPS. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
9 analysts have issued twelve-month price targets for Epizyme's stock. Their predictions range from $11.00 to $25.00. On average, they expect Epizyme's share price to reach $18.50 in the next year. This suggests a possible upside of 43.9% from the stock's current price. View Analyst Price Targets for Epizyme.
What is the consensus analysts' recommendation for Epizyme?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.
Has Epizyme been receiving favorable news coverage?
News articles about EPZM stock have trended positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Epizyme earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Epizyme.
Are investors shorting Epizyme?
Epizyme saw a increase in short interest in the month of July. As of July 15th, there was short interest totalling 7,444,000 shares, an increase of 17.3% from the June 15th total of 6,346,400 shares. Based on an average daily trading volume, of 886,200 shares, the days-to-cover ratio is presently 8.4 days. Currently, 12.8% of the company's stock are short sold. View Epizyme's Current Options Chain.
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Allakos (ALLK), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Alkermes (ALKS), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Mirati Therapeutics (MRTX), Arrowhead Pharmaceuticals (ARWR), Taro Pharmaceutical Industries (TARO) and Nektar Therapeutics (NKTR).
What other stocks do shareholders of Epizyme own?
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
- Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
- Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
- Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
- Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)
Who are Epizyme's major shareholders?
Epizyme's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (11.27%), Vanguard Group Inc. (7.79%), BlackRock Inc. (7.07%), NEA Management Company LLC (4.82%), Rock Springs Capital Management LP (2.04%) and Victory Capital Management Inc. (1.85%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert B Bazemore. View Institutional Ownership Trends for Epizyme.
Which institutional investors are selling Epizyme stock?
EPZM stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Point72 Asset Management L.P., D. E. Shaw & Co. Inc., Artal Group S.A., A.R.T. Advisors LLC, Morgan Stanley, Virtus ETF Advisers LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros and Robert B Bazemore. View Insider Buying and Selling for Epizyme.
Which institutional investors are buying Epizyme stock?
EPZM stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Rhenman & Partners Asset Management AB, Renaissance Technologies LLC, Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, First Light Asset Management LLC and Alps Advisors Inc.. View Insider Buying and Selling for Epizyme.
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $12.86.
How big of a company is Epizyme?
Epizyme has a market capitalization of $1.17 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.
What is Epizyme's official website?
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
